Ken Griffin Renalytix PLC Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.21 - $0.45 $2,877 - $6,165	13,700 New	13,700 $2,000
Q4 2023 Feb 14, 2024	BUY	$0.33 - $1.61 $4,356 - $21,252	13,200 Added 573.91%	15,500 $6,000
Q3 2023 Nov 14, 2023	SELL	$1.51 - $4.01 $9,513 - $25,263	-6,300 Reduced 73.26%	2,300 $3,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $2.92 $6,800 - $9,928	3,400 Added 65.38%	8,600 $25,000
Q1 2023 May 15, 2023	SELL	$1.93 - $3.72 $1,737 - $3,348	-900 Reduced 14.75%	5,200 $12,000
Q4 2022 Feb 14, 2023	BUY	$1.06 - $2.21 $6,466 - $13,481	6,100 New	6,100 $11,000

3.88M

13.7K

Ticker RNLX
Exchange OTC
Sector Healthcare
Industry Health Information Services
Shares Outstandng 37,445,900
Market Cap $5.62M
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.